Skip to content
Open access

Long-term outcomes of anti-VEGF therapy during cataract surgery in eyes with diabetic macular edema: a five-year retrospective cohort study.

Oct 2026 · International Journal of Ophthalmology · Vol 19 10, pp. 2010-2017 · 0 citations
Medicine

Abstract

Aim

To evaluate the long-term outcomes of anti-vascular endothelial growth factor (VEGF) therapy during cataract surgery in eyes with diabetic macular edema (DME).

Methods

This was a retrospective clinical study. Patients with DME scheduled for cataract surgery were included. Prior to surgery, DME was considered adequately controlled, defined as a central subfield thickness (CST) of ≤300 µm without evidence of significant intraretinal or subretinal fluid on optical coherence tomography. Participants were divided into two groups: 18 patients underwent cataract surgery alone, and 10 received both cataract surgery and anti-VEGF therapy concurrently. The study compared the timing of the initial postoperative anti-VEGF injection and the frequency of injections over 5y. Postoperative outcomes, particularly improvements in best-corrected visual acuity (BCVA) and changes in CST, were also examined.

Results

A total of 28 patients were enrolled, with 10 patients undergoing combined cataract surgery and anti-VEGF therapy (3 males, 62.8±4.4y), while 18 patients (7 males, 70.0±13.6y) underwent cataract surgery alone. The combined therapy group had a significantly longer interval before the initial postoperative anti-VEGF injection (12.2±5.7wk) compared to the cataract-only group (4.4±1.6wk). The combined therapy group also required significantly fewer total anti-VEGF injections over 1, 3, and 5y, with the most notable difference in the first year. There was significant improvement in BCVA from pre- to postoperative stages across all eyes. However, there was no statistically significant difference in postoperative BCVA and CST between the groups.

Conclusion

Concurrent anti-VEGF therapy during cataract surgery is associated with lower early postoperative DME recurrence and a longer interval to the first postoperative anti-VEGF injection. This combined approach may reduce early treatment burden.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.